



Prof. Dr. Horst Domdey

Born: 1951

Prof. Dr. Horst Domdey, a trained biochemist, held research positions in Germany, Switzerland and the United States, such as ISREC, UCSD, the California Institute of Technology and the Munich Gene Center, before he became Professor of Biochemistry at the Ludwig Maximilian University of Munich in 1994. In the same year he co-founded Medigene, one of the first biotech companies in Germany. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he has been the Managing Director of BioM, the cluster development and management organization of the Munich Biotech Cluster. Since 2006 he also oversees the Bavarian Biotechnology Cluster, and since 2010 he is the spokesman of the Munich Leading Edge Cluster Program m4. In addition, Prof. Domdey is member of the Supervisory Board of the Max Delbrueck Center for Molecular Medicine, member of the Board of Directors of the Peter and Traudl Engelhorn Foundation and of the Board of the Foundation for Stem Cell Research and Applied Regenerative Medicine.

Essential positions:

- Managing Director of BioM Biotech Cluster Management GmbH, Planegg, Germany
- Liquidator of BioM AG Munich Biotech Development i.L., Planegg, Germany

Antoinette Hiebeler-Hasner



Born: 1958

Mrs. Hiebeler-Hasner has started her career with Peat Marwick Mitchell & Co. now KPMG after having studied business administration at the Ludwigs-Maximilians University in Munich. As a tax consultant she founded her own tax consultancy firm in 1988. After various mergers with other consultancies the optegra consultancy group was established, with offices in Cologne and in Munich. With more than 140 employees optegra provides services such as legal and tax consulting, as well as auditing. Since October 2017, this company has been operating as Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft after the integration of the optegra Group into the globally active Vistra Group. Since 1.10.2018, Ms. Hiebeler-Hasner has been Country Country Director for all Vistra companies in Germany. Furthermore, Mrs. Hiebeler-Hasner and her brothers founded the H3 Aerospace GmbH & Co.KG, which purchased the Grob Aircraft AG in 2009. Grob Aircraft SE is a medium-sized company, with more than 250 employees, which develops and produces training aircrafts that are successfully sold world-wide. Apart from the professional abilities of Mrs. Hiebeler-Hasner, which include proficiency with regard to financial statements, securing of accounting continuity and tax consultancy, Mrs. Hiebeler-Hasner is also able to offer a huge entrepreneurial expertise due to her various business activities.

Essential positions:

- Chairperson of the Supervisory Board of Grob Aircraft SE
- Chairperson of the Supervisory Board of Ventuz Technology AG
- Country Managing Director Vistra Germany Managing Director of Wilder Kaiser GmbH Steuerberatungsgesellschaft (Tax Consultants)



Yita Lee, Ph.D.

Born: 1971

Yita Lee currently serves as Deputy Chairman and Chief Scientific Officer of Sinphar Group, a publicly listed pharmaceutical company where he oversees the progress of the company's R&D projects. As the President of Sinphar's North American subsidiary, CanCap Pharmaceutical Ltd., (British Columbia, Canada) he is responsible for the running of the business in the region. He also is the Deputy Chairman of publicly listed SynCore Biotechnology Co., Ltd., a drug development company with comprehensive pipeline of novel drugs; and serves as Director of ZuniMed Biotech Co., Ltd., a GMP manufacturer of medical devices and pharmaceutical containers. Yita Lee earned his Ph.D. degree at Michael Smith Laboratories & Department of Chemical and Biological Engineering, University of British Columbia and EMBA from the National Taiwan University. He is currently a director of the Taiwan Bio Industry Organization, and Taiwan Listed Cabinet Company Association. He was previously director of the Monte Jade Science and Technology Association (Canada) in 2006.

Essential positions:

Publicly listed companies:

- Sinphar Pharmaceutical Co., Ltd., Taiwan: Deputy Chairman and Chief Scientific Officer
- SynCore Biotechnology Co., Ltd., Taiwan: Deputy Chairman

Other companies/organizations:

- CanCap Pharmaceutical Ltd., Canada: President
- ZuniMed Biotech Co., Ltd., Taiwan: Director
- Taiwan Bio Industry Organization, Taiwan: Director
- Taiwan Listed Cabinet Company Association: Director

Dr. Keith Manchester

Born: 1968

Keith Manchester serves as a Partner and the Head of Life Sciences at QVT Financial LP, New York, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life sciences companies. Dr. Manchester also serves as a director of Arbutus Biopharma Corporation and Roivant Sciences, Inc. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

Essential positions:

Publicly listed companies:

- Arbutus Biopharma Corporation, Canada: Director since 2015

Other companies/organizations:

- Partner and Head at Life Sciences QVT Financial LP
- Roivant Sciences, Inc., Delaware, USA: Director since 2014, and Roivant Sciences Ltd., Bermuda: Director since 2014

Ronald Scott



Born: 1955

Ronald Scott was elected as a member of the Basilea Pharmaceutical International Ltd., Basel, Switzerland, Board of Directors (Verwaltungsrat) in April 2018. He served as Basilea's Chief Executive Officer from January 2013 until April 2018. He was Basilea's Chief Operating Officer from January through December 2012, and served as Basilea's Chief Financial Officer from the Company's founding in 2000 through January 2012 as well as ad interim Chief Financial Officer from February 2013 until November 2013. From 2004 to October 2011, Mr. Scott served on the Board of Directors and was a co-founding Board member in 2000. Prior to joining Basilea, Mr. Scott worked at Roche Holding AG (Roche) in management positions in Pharmaceutical Finance, Licensing, and the Roche Corporate Finance Mergers and Acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as Director in Prudential's Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a bachelor's degree from Utah State University (USA) and a master's degree from Harvard University (USA).

Essential positions:

- Member of the Board of directors (Verwaltungsrat), Basilea Pharmaceutical International Ltd., Basel, Switzerland
- Member of the Board of directors (Verwaltungsrat), KIDpharma AG, Root, Schweiz



Dr. Gerd Zettlmeissl

Born: 1955

Dr. Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies.

Until early 2015 he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline. He is the former CEO of the Austrian-based biotechnology company Intercell AG (now Valneva SE). While at Intercell AG from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring GmbH and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.

Essential positions:

- MSD Wellcome Trust Hilleman Laboratories, New Delhi, India: Chairman of the Supervisory Board since 2013
- Themis Bioscience GmbH, Vienna, Austria: Chairman of the Supervisory Board since 2015



Dr. Frank Mathias

Born: 1962

Dr. Frank Mathias is Chief Executive Officer of Rentschler Biopharma SE since April 2016. Dr. Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 30 years' experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst AG. After that, he became General Manager of the successful and renowned companies Servier Deutschland GmbH and Amgen Deutschland GmbH in Munich. Dr. Mathias was Chief Executive Officer of the Medigene AG from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer taken the responsibility for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies.

Essential positions:

- CEO of Rentschler SE, Laupheim, Germany (private company)
- Chairperson of the Supervisory Board of Mediatum AG, Heidelberg, Germany (private company)
- Member of the Supervisory Board of Leukocare AG, Martinried, Germany Germany (private company)
- Chairperson of the Advisory Board of August Faller GmbH & Co. KG, Waldkirch, Germany Germany (private company)